Literature DB >> 10967566

Blood stem cell collections in multiple myeloma: definition of a scoring system.

A Corso1, S Caberlon, G Pagnucco, C Klersy, P Zappasodi, E P Alessandrino, L Vanelli, S Mangiacavalli, M Lazzarino, C Bernasconi.   

Abstract

The purpose of the study was to identify factors that could predict good yields of peripheral blood stem cells (PBSC) in multiple myeloma (MM). Fifty-one MM patients, nine with refractory disease and 42 in plateau phase, were mobilized with high-dose cyclophosphamide (HD-Cy) at 4 g/m2 followed by granulocyte colony-stimulating factor (G-CSF) 5 microg/kg/day. Clinical and laboratory parameters at the time of mobilization were analyzed for correlations with the number of CD34+ cells collected, with the colony-forming unit granulocyte-macrophage (CFU-GM) count, and the mononuclear cell (MNC) count. In univariate analysis, low WBC count, low platelet count, prior exposure to melphalan, and an interval >6 months from the start of treatment correlated with poor yields of CD34+ cells. Low platelet count, prior exposure to melphalan or to radiotherapy, and an interval >6 months from the start of treatment were associated with a low CFU-GM count. On the basis of these data, we defined a scoring system able to predict the yield of the mobilizing procedure. According to this system, the presence of more than one risk factor (low WBC and platelet counts, prior exposure to melphalan, interval from first chemotherapy >6 months) was predictive of insufficient collections when a conventional combination of mobilizing measures are used.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10967566     DOI: 10.1038/sj.bmt.1702514

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.

Authors:  Ivana N Micallef; Patrick J Stiff; Edward A Stadtmauer; Brian J Bolwell; Auayporn P Nademanee; Richard T Maziarz; Angela M Partisano; Sachin Marulkar; John F DiPersio
Journal:  Am J Hematol       Date:  2013-09-09       Impact factor: 10.047

2.  Successful mobilization of peripheral blood stem cells with bortezomib + high-dose cyclophosphamide + G-CSF in a light chain myeloma patient after failure with Total Therapy 2.

Authors:  Gianfranco Giglio; Sante Romito; Francesco Carrozza; Michela Musacchio; Giustino Antuzzi; Rosanna Gigli; Marilù Magri; Pasqua Bavaro; Paolo Di Bartolomeo; Mario Dell'Isola; Patrizia Accorsi
Journal:  Int J Hematol       Date:  2009-06-16       Impact factor: 2.490

3.  Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result.

Authors:  Marc-Andrea Baertsch; Katharina Kriegsmann; Petra Pavel; Thomas Bruckner; Michael Hundemer; Mark Kriegsmann; Anthony D Ho; Hartmut Goldschmidt; Patrick Wuchter
Journal:  Transfus Med Hemother       Date:  2017-10-04       Impact factor: 3.747

4.  Poor hematopoietic stem cell mobilizers in multiple myeloma: a single institution experience.

Authors:  Guillermo J Ruiz-Delgado; Avril López-Otero; Ana Hernandez-Arizpe; Aura Ramirez-Medina; Guillermo J Ruiz-Argüelles
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-06-21       Impact factor: 2.576

5.  Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.

Authors:  Cyrille Hulin; Fritz Offner; Philippe Moreau; Murielle Roussel; Karim Belhadj; Lotfi Benboubker; Denis Caillot; Thierry Facon; Laurent Garderet; Frédérique Kuhnowski; Anne-Marie Stoppa; Brigitte Kolb; Mourad Tiab; Kon-Siong Jie; Matthijs Westerman; Jérôme Lambert; Lixia Pei; Veronique Vanquickelberghe; Carla De Boer; Jessica Vermeulen; Tobias Kampfenkel; Pieter Sonneveld; Niels W C J Van de Donk
Journal:  Haematologica       Date:  2021-08-01       Impact factor: 9.941

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.